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Abstract Cell labeling with magnetic iron oxide nanoparticles (IONPs) is increasingly a routine approach in the cell-
based cancer treatment. However, cell labeling with magnetic IONPs and their leading effects on the biological properties
of human lung carcinoma cells remain scarcely reported. Therefore, in the present study the magnetic c-Fe2O3
nanoparticles (MNPs) were firstly synthesized and surface-modified with cationic poly-L-lysine (PLL) to construct the
PLL-MNPs, which were then used to magnetically label human A549 lung cancer cells. Cell viability and proliferation
were evaluated with propidium iodide/fluorescein diacetate double staining and standard 3-(4,5-dimethylthiazol-2-diphe-
nyl-tetrazolium) bromide assay, and the cytoskeleton was immunocytochemically stained. The cell cycle of the PLL-MNP-
labeled A549 lung cancer cells was analyzed using flow cytometry. Apoptotic cells were fluorescently analyzed with
nuclear-specific staining after the PLL-MNP labeling. The results showed that the constructed PLL-MNPs efficiently
magnetically labeled A549 lung cancer cells and that, at low concentrations, labeling did not affect cellular viability,
proliferation capability, cell cycle, and apoptosis. Furthermore, the cytoskeleton in the treated cells was detected intact in
comparison with the untreated counterparts. However, the results also showed that at high concentration (400 lg mL-1),
the PLL-MNPs would slightly impair cell viability, proliferation, cell cycle, and apoptosis and disrupt the cytoskeleton in
the treated A549 lung cancer cells. Therefore, the present results indicated that the PLL-MNPs at adequate concentrations
can be efficiently used for labeling A549 lung cancer cells and could be considered as a feasible approach for magnetic
targeted anti-cancer drug/gene delivery, targeted diagnosis, and therapy in lung cancer treatment.
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1 Introduction
Lung cancer is the most common cause of cancer-related
deaths worldwide [1, 2]. According to the US National
Cancer Institute, approximately 226, 160 new lung cancers
were diagnosed and 160, 340 lung cancer-related deaths
were recorded in the US at the end of 2012. Despite
advances in cancer research, the discovery of lung cancer
biomarkers has not significantly improved conventional
treatments in recent years [3]. Therefore, the development
of novel approaches for the detection of early lung cancer-
specific markers for personalized treatment is urgently
needed to increase patient survival in lung cancer treatment.
Nanotechnology has provided new perspectives for
molecular detection, cellular imaging, and screening in
cancer treatment. Despite the fact that nanotechnology can
provide sensitive and specific information from lung cancer
patients, the selective delivery of anti-cancer drugs to tumor
sites in lung cancer treatment is also highly desirable [4, 5].
Magnetic nanoparticles (IONPs) (mostly c-Fe2O3 and
Fe3O4) have received an increasing interest in biomedical
applications because of their low toxicity, outstanding
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biocompatibility, and superparamagnetic properties appli-
cable in cell labeling and separation [6, 7], cell imaging [8,
9], cell-based therapy [10, 11], magnetofection [12], and
tissue engineering and repair [13, 14], among other uses.
Further, IONPs have a large surface area engineered with a
number of functional groups capable of cross-linking to
tumor-targeting ligands, such as antibodies, peptides, or
small molecules, for diagnostic imaging or delivery of
therapeutic agents [15–17]. IONPs for cell labeling have
been widely used to isolate cells of interest from a hetero-
geneous population within a magnetic field via phenotypic
markers tagged with magnetic particles [18, 19]. The
labeling of cells with IONPs allows to noninvasively
monitor the migration, biodistribution, and behavior of
targeted cells. Therefore, the efficient magnetic labeling of
targeted cells offers promising new approaches in cell-
based therapy with great potential for cancer treatment [20].
The magnetic labeling of cells can be performed fol-
lowing either of two approaches: (i) the direct attachment
of magnetic particles to the cell surface [21] or (ii) the
receptor-mediated or transfection agent-mediated endocy-
tosis pathway which internalizes biocompatible magnetic
particles [16]. A variety of competent ligands and target
agents conjugated onto nanoparticle surfaces, including
monoclonal antibodies, transferrin, and folic acid, have
been used to target cell surfaces [22–24]. The endocytosis
pathway, which involves the transfection of IONPs into
cells, requires a high rate of nanoparticle internalization by
the cells. However, both the cell membrane and IONPs are
usually negatively charged, leading to the inefficient
labeling of targeted cells because of repulsive electric
interactions. Therefore, the complexing of positively
charged transfection agents, such as polyethylenimine [25,
26], lipofectamine [27, 28], poly-L-lysine (PLL) [29, 30],
and protamine sulfate [31, 32], is often introduced to
enhance cell labeling efficiency through favorable elec-
trostatic interactions between the target cells and trans-
fection agent-modified IONPs. PLL is commonly used to
enhance cell adhesion on the surface of culture dishes and
is a potent modifier for IONPs [33]. A PLL coating on
IONPs could lead to improved electrostatic binding on
target cells and thus enhance cellular uptake.
In the present study, the PLL-modified MNPs were
constructed to label human A549 lung cancer cells. Com-
pared with previous studies [34, 35], the present study
attempted to use cationic transfection agent PLL coupled
with MNPs to enhance the cellular uptake of nanoparticles
in human A549 lung cancer cells. Furthermore, the effects
of magnetic labeling on the biological properties of A549
lung cancer cells, including cell viability, proliferation
capacity, cytoskeletal disruption, cell cycle, and apoptosis,
were investigated separately. The morphology and struc-
ture of the PLL-MNPs were characterized by transmission
electron microscopy (TEM), X-ray diffraction (XRD),
Fourier transform infrared spectroscopy (FT-IR), and
vibrating sample magnetometry. The iron uptake of mag-
netically labeled A549 lung cancer cells was confirmed
with histological Prussian blue staining. The viability of
magnetically labeled A549 lung cancer cells was assessed
by fluorescein diacetate (FDA) and propidium iodide (PI)
double staining. The cytoskeletal disruption and apoptosis
rate of magnetically labeled A549 lung cancer cells was
assayed by rhodamine-conjugated phalloidin and fluores-
cent bisbenzimide dye (Hoechst H33258). The cell cycle of
the labeled A549 lung cancer cells was analyzed by flow
cytometry. Taken together, this study provides insights into
the effects of magnetic labeling on the biological properties
of A549 lung cancer cells and facilitates the MRI-assisted
tracking and in vivo monitoring of their survival, migra-
tion, and transformation, which would be of great interest
for targeted lung cancer cell treatment.
2 Experimental
2.1 Reagents and Materials
The superparamagnetic c-Fe2O3 NPs utilized in this study
were prepared from magnetite (Fe3O4) according to the
methods proposed elsewhere [36, 37]. The human lung
alveolar carcinoma epithelial cells (A549) were obtained
from the Shanghai Cell Bank of the Chinese Academy of
Sciences (Shanghai, China). The cell culture medium and
fetal bovine serum (FBS) were purchased from Gibco
Invitrogen Corporation (CA, USA). PLL (Mw = 338,100),
3-(4,5-dimethylthiazol-2-diphenyl-tetrazolium) bromide
(MTT), potassium ferrocyanide (Perls reagent), FDA, PI,
RNase, Hoechst H33258, dimethyl sulfoxide (DMSO),
Triton X-100 solution, glutaraldehyde, and paraformalde-
hyde were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Neutral red was obtained from Beyotime Biotech
(Jiangsu, China). Fluorescent dye 4,6-diamidino-2-
phenylindole (DAPI) was purchased from Molecular
Probes Inc. (Eugene, OR, USA). Rhodamine phalloidin
was obtained from Cytoskeleton Inc. (Denver, CO, USA).
Other reagents and chemicals were purchased from local
commercial suppliers and were of analytical reagent grade,
unless otherwise stated. Deionized water (Milli-Q, Milli-
pore, Bedford, MA, USA) was used to prepare aqueous
solutions.
2.2 Principle of A549 Lung Cancer Cell Labeling
with PLL-Modified MNPs
Following modification of magnetic c-Fe2O3 nanoparticles
(MNPs) with PLL to create the PLL-MNPs, the latter was
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putatively delivered to human A549 lung cancer cells
(Scheme 1). Subsequently, the effects of the PLL-MNPs on
the biological properties of A549 lung cancer cells,
including proliferation capacity, cell viability, actin
cytoskeleton disruption, and apoptosis rate, were further
investigated after magnetic labeling. Therefore, this work
would clearly elaborate the effects of magnetic labeling on
biological properties of lung cancer cells using the con-
structed PLL-MNPs, facilitating IONP-assisted targeted
drug and/or gene delivery in cancer treatment.
2.3 Synthesis and Characterization of the PLL-
MNPs
MNPs used in the study were prepared and characterized as
previously described elsewhere [36, 37], and the PLL
modification was then performed to enhance cellular
uptake to NPs [38]. Briefly, 3.6 mL of MNPs (2 mg mL-1)
were mixed with 3.6 mL of serum-free RPMI-1640 med-
ium, followed by the addition of 0.8 mL of PLL
(0.45 mg mL-1). The solution containing MNPs and PLL
was then incubated with low-speed stirring for 2 h at
200 rpm, and the prepared PLL-modified MNPs were
washed to remove residual PLL with serum-free RPMI-
1640 medium under the magnetic field for three times.
Finally, the PLL-MNPs were vacuum desiccated and stored
at 4 C until further use.
The morphology of MNPs and PLL-MNPs was char-
acterized by TEM using a Hitachi H-600 microscope (Ja-
pan). The crystal structure of MNPs was characterized by
an X-ray diffractometer (Philips D/Max-2500, Holland)
using a monochromatized X-ray beam with nickel-filtered
Cu-Ka radiation. FT-IR (Nicolet NEXUS 670, USA) was
performed to record the spectra of MNPs and PLL-MNPs.
Magnetic measurements of the PLL-MNPs were performed
on a vibrating sample magnetometer (Lakeshore-7304,
USA) by changing H between ?1375 and -1375 Oe.
2.4 Cell Culture
The human A549 lung cancer cells were routinely cultured
in RPMI-1640 medium supplemented with 10 % (v/v)
heat-inactivated FBS, 1 % L-glutamine, 1 % penicillin
(100 U mL-1), and 1 % streptomycin (100 lg mL-1) in a
humidified incubator at 37 C in the presence of 5 % CO2.
The cells were regularly monitored using an inverted light
microscope, and the culture medium was changed every
2 days. The cells were normally passaged in 1:3 ratios
every 3 days to maintain an exponential growth phase.
2.5 Labeling of A549 Lung Cancer Cells
with the PLL-MNPs
The A549 cells at the exponential growth phase were
treated with 0.25 % trypsin in Ca?- and Mg?-free phos-
phate-buffered saline (PBS, pH 7.4) for 5 min at 37 C to
prepare a cell suspension. The cells were counted using a
regular hemocytometer and then seeded at a density of
2 9 104 cells/well in a 24-well plate. Different concen-
trations of the PLL-MNPs were then added to the 24-well
plates separately. The culture medium was discarded after
incubation for 48 h, and the PLL-MNP-labeled A549 cells
were then incubated with a mixture (50:50, v/v) of 2 %
potassium ferrocyanide (Perls reagent) and 2 %
hydrochloric acid for 30 min following fixation with 4 %
paraformaldehyde. Counterstaining was performed by
incubating the cells with neutral red for 2 min. Unlabeled
A549 cells were used as the control.
2.6 A549 Cell Proliferation Capacity Assay
after PLL-MNP Labeling
The standard MTT method was used to evaluate the pro-
liferation capacity of A549 lung cancer cells after PLL-
MNP labeling. The A549 cells were harvested to prepare a
cell suspension at the exponential growth phase and then
seeded at a density of 1 9 104 cells/well in a 96-well
microwell plate. The PLL-MNPs were added to the
microwell plates at final concentrations ranging from 25 to
400 lg mL-1. The culture medium was removed after
incubation for 48 h and 200 lL of the prepared MTT
solution (final concentration: 0.5 mg mL-1) was then
















Scheme 1 Schematic representation of the PLL-MNP preparation
and delivery to human A549 lung cancer cells
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150 lL DMSO. Finally, the absorbance of the prepared
solutions was measured at 570 nm on a microplate spec-
trophotometer (Bio Tek Instrument Inc., USA). Unlabeled
A549 cells were used as the control.
2.7 A549 Lung Cancer Cell Viability Assay
after PLL-MNP Labeling
The cell viability of PLL-MNP-labeled A549 cells was
assessed by the FDA and PI double-staining protocol [39,
40]. The A549 cells were seeded and incubated for 12 h at
a density of 2 9 104 cells/well in a 24-well plate. The PLL-
MNPs were added to the plate at final concentrations
ranging from 25 to 400 lg mL-1. Subsequently, the FDA
(final concentration: 1 lg mL-1) and PI solutions (final
concentration: 20 lg mL-1) were successively introduced
into the culture plates. The cellular viability was then
analyzed by counting the live and dead cells after incu-
bation for 10 min at room temperature. The living cells
were stained green by FDA, whereas the dead cells were
stained red by the fluorescent PI dye. The samples were
analyzed with an inverted fluorescence microscope equip-
ped with a high-resolution CCD camera. Unlabeled A549
cells were used as the control.
2.8 Immunofluorescent Staining of Actin
Cytoskeleton
The morphology and F-actin cytoskeletal structure of A549
cells exposed to varying concentrations of the PLL-MNPs
were investigated. Actin cytoskeleton staining was per-
formed using rhodamine phalloidin following the kit’s
protocol with minor modifications. Briefly, the A549 cells
were seeded in the PLL-coated 24-well plates, cultured for
12 h, and then treated with the PLL-MNPs in an RPMI-
1640 medium. The PLL-MNP-labeled A549 cells were
then fixed with 2.5 % glutaraldehyde for 10 min at room
temperature, and 0.5 % Triton X-100 solution in PBS was
introduced to permeabilize the cells by culturing for 5 min
at room temperature. The permeabilized cells were washed
with PBS (pH 7.4) for three times and then refilled with
200 lL of 100 nM rhodamine phalloidin. Sequentially, the
cells were incubated in the dark for 30 min at room tem-
perature. The cells were counterstained with DAPI dye to
reveal nuclei. Finally, the samples were observed under an
inverted fluorescence microscope equipped with a high-
resolution CCD camera.
2.9 Cell Cycle Analysis of PLL-MNP-Labeled A549
Lung Cancer Cells
The cell cycle of PLL-MNP-labeled A549 cells was ana-
lyzed by flow cytometry. The PLL-MNP- treated A549
cells were firstly harvested and dissociated into a single-
cell suspension, and 1 9 106 cells were resuspended in
500 lL of PBS solution after washing three times. The
A549 cells were then fixed by adding 2 mL of 70 % ice-
cold ethanol, followed by overnight incubation at 4 C.
The prepared cell suspension was then centrifuged to dis-
card the fixative, resuspended in 2 mL of PBS solution, and
filtered using a 200-mesh cell screen. The pelleted cells
were resuspended in 1 mL of 50 lg mL-1 PI solution
containing 20 lg mL-1 RNase for cell staining. The A549
cells were incubated in the dark at 4 C for 1 h, analyzed
using a FACSCalibur flow cytometer (BD Biosciences, San
Jose, CA), and analyzed using CELLQUEST software (BD
Biosciences). The untreated A549 cells were used as
controls.
2.10 Fluorescent Staining of Apoptotic Cells
To visualize apoptotic cells, the PLL-MNP-labeled A549
cells were fixed with 4 % paraformaldehyde for 15 min
and then stained with Hoechst H33258 solution (concen-
tration: 2 lg mL-1) for 10 min at room temperature. The
stained cells were rinsed with PBS three times and then
observed via an inverted fluorescence microscope equipped
with a high-resolution CCD camera. Untreated A549 cells
were used as the control.
2.11 Instruments
A transmission electron microscope (TEM, Hitachi H-600,
Japan) was employed to characterize the morphology and
structure of the prepared MNPs and PLL-MNPs. The
crystal structure of MNPs was analyzed with an X-ray
diffractometer (XRD, Philips D/Max-2500, Holland) using
a monochromatic X-ray beam with nickel-filtered Cu-Ka
radiation. Magnetic measurements of PLL-MNPs were
carried out on a vibrating sample magnetometer (LAKE-
SHORE-7304, USA) by changing H between ?1375 and
-1375 Oe. Fluorescence images were acquired using an
inverted fluorescence microscope (Eclipse TE 2000-U,
Nikon, Kyoto, Japan) equipped with a high-resolution CCD
camera (CV-S3200, JAI Co., Japan). The cell cycle of the
PLL-MNP-labeled A549 cells were analyzed using FACS
Calibur flow cytometer (BD Biosciences, San Jose, CA).
2.12 Image Acquisition and Analysis
Bright-field and fluorescence images were acquired using
an inverted fluorescence microscope (Eclipse TE 2000-U,
Nikon, Kyoto, Japan) equipped with a CCD camera (CV-
S3200, JAI Co., Japan). Software Image-Pro Plus 6.0
(Media Cyternetics) and SPSS 12.0 (SPSS Inc.) were used
to perform image analysis and statistical data analysis,
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respectively. The quantitative data are presented as
mean ± standard deviation for each experiment. All
experiments were performed with at least three replicates,
and the results presented were obtained from representative
experiments.
3 Results and Discussion
3.1 Synthesis and Characterization of MNPs
and PLL-MNPs
Figure 1a shows a TEM image of the MNPs indicating
the synthesis of nanosized MNPs. The diameter of a
single MNP was approximated to be in the range of
10–15 nm. The electron diffraction pattern (Fig. 1b),
corresponding to bright-field images, showed that these
particles consisted of MNPs. This was also confirmed by
their XRD patterns (Fig. 1c), which proved that their
crystalline nature and the peaks matched standard c-
Fe2O3 reflections; no a-Fe2O3 phase was observed,
although the product was brown. Figure 1d shows the
TEM image of the prepared PLL-MNPs, indicating that
the PLL modification did not significantly affect the
nanosized structure or morphology, consistent with
observations in previous studies [41, 42].
FT-IR spectra of the MNPs and PLL-MNPs confirmed
that MNPs were successfully modified by PLL, because the
characteristic adsorption band of Fe–O was observed at
554 cm-1 (Fig. 2a). The magnetization curve of the pre-
pared PLL-MNPs demonstrated a symmetrical hysteresis
loop (Fig. 2b), which is characteristic of superparamag-
netism. In other words, the PLL-MNPs become magnetized
in the presence of a magnetic field and, once the field is
removed, only a minimal residual magnetization remains
within the particles [43]. This characteristic makes the
prepared PLL-MNPs ideal as magnetic target carriers.
Moreover, the saturation magnetization and coercivity of
the PLL-MNPs were also estimated to be approximately
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Fig. 1 a TEM image, b EDX results, and c XRD pattern of MNPs. d TEM image of PLL-MNPs
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3.2 Labeling of A549 Lung Cancer Cells
with the PLL-MNPs
A549 cells were treated with the prepared magnetic PLL-
MNPs for cell labeling. The Prussian blue method was
employed to detect iron within the treated cells through the
reduction of ferric iron into the ferrous state as indicated by
a blue precipitate [44]. The results showed that the blue
precipitate formed, indicating the presence of the PLL-
MNPs within A549 cells (Fig. 3).
3.3 Proliferation Capacity of PLL-MNP-Labeled
A549 Lung Cancer Cells
The MTT assay is a simple colorimetric method used to
measure cell proliferation [35, 45]. A549 cells were incubated
with the PLL-MNPs at different concentrations varying from
25 to 400 lg mL-1; unlabeled A549 cells were used as the
control. The results indicated that the A549 cells labeled with
PLL-MNPs at low concentrations, ranging from 25 to
200 lg mL-1, generally exhibited a comparable proliferation
ability in contrast with the unlabeled cells. However, A549
cells labeled with the PLL-MNPs at a concentration of
400 lg mL-1 showed a reduced proliferation potential
(Fig. 4). Therefore, the results indicate that the proliferation
capacity of the A549 cells was not obviously affected by
magnetic labeling of the PLL-MNPs at low concentrations.
3.4 Cell Viability of PLL-MNP-Labeled A549 Lung
Cancer Cells
The PI and FDA double-staining protocol was used to
detect the cell viability of PLL-MNP-labeled A549 cells. PI
is a DNA-binding fluorescent dye that only enters dead or
dying cells with damaged or leaky membranes; therefore, it
is used as a marker for apoptotic and necrotic cells [39, 40].
On the other hand, FDA, which stains cells with intact
membranes, produces a bright green fluorescence [39, 40].
The results showed that the PLL-MNP-labeled A549 cells
exhibited intact viability compared with the unlabeled
A549 cells (Fig. 5).
3.5 Actin Cytoskeleton of PLL-MNP-Labeled A549
Lung Cancer Cells
Cytoskeleton microfilaments are commonly involved in
normal cell attachment and morphology [46, 47]; thus,
the altered appearance of actin filaments in the PLL-
MNP-labeled A549 cells could indicate that the PLL-
MNPs are highly cytotoxic. Rhodamine phalloidin
specifically binds to the polymerized F-actin with a high
affinity. The immunocytochemical staining of the actin
cytoskeleton in the PLL-MNP-labeled A549 cells is
shown in Fig. 6. The results show that the A549 cells
labeled with the PLL-MNPs at concentrations ranging
from 25 to 200 lg mL-1 exhibited normal cytoskeleton
organization compared with their untreated counterparts.
However, when the concentration of the PLL-MNPs
increased to 400 lg mL-1 in the labeled cells, the
cytoskeleton was slightly affected as observed by a rel-
atively small and round morphology and a slight disor-
ganization of F-actin. Therefore, these data indicate that
the PLL-MNPs, at appropriate concentrations, could be
used for the cell labeling of human A549 lung cancer
cells.























Fig. 2 a FT-IR spectra of MNPs (top), PLL-MNPs (middle), and pure PLL (bottom). b The magnetic loop of PLL-MNPs at 300 K
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3.6 Effects of PLL-MNP Labeling on the Cell Cycle
of A549 Cells
The effects of PLL-MNP treatment on the cell cycle dis-
tribution of A549 cells were analyzed using PI staining and
a flow cytometer. The results showed that the DNA com-
position in S-phase is 23.49 % for the unlabeled A549 cells
(Fig. 7a) and that the DNA composition in S-phase of the
PLL-MNP-labeled A549 cells with different concentrations
of PLL-MNPs is 26.35, 23.87,27.95,24.02, and 26.44 %
(Fig. 7b–f). Also, there are no obvious differences in other
phases. The results indicated that PLL-MNP treatment did
not affect distribution of cell cycle for A549 cells.
3.7 Apoptosis Assay
Cell apoptosis is a distinct process of programed cell death
and plays an important role in carcinogenesis and cancer
treatment. Apoptosis is generally characterized by distinct
morphological characteristics of related cells, which usu-
ally include blebbing, cell shrinkage, nuclear fragmenta-
tion, chromatin condensation, and chromosomal DNA
fragmentation [48, 49]. In contrast, tumor cells are char-
acterized by their ability to bypass apoptosis. Thus, apop-
tosis is commonly used as a vehicle for targeted cell
treatment in cancer therapy [50, 51]; medications used to
induce apoptosis of tumor cells are a major focus of cancer
treatment.
In the present study, A549 cells were treated with
different concentrations of the PLL-MNPs and then
stained with fluorescent dye Hoechst H33258, a bisben-
zimide dye that binds to AT-rich regions of DNA
allowing the detection and relative quantitation of apop-
totic cell DNA [52, 53]. To visualize the nuclear frag-
mentation of apoptotic cells, the typical changes of treated
Fig. 3 Prussian blue staining of A549 lung cancer cells labeled with PLL-MNPs at different concentrations (25, 50, 100, 200, and 400 lg mL-1
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Concentration of PLL-γ-Fe2O3 NPs (μg mL−1)
Fig. 4 The temporal growth state of the PLL-MNP-labeled A549
lung cancer cells incubated in RPMI-1640 medium, and the untreated
counterparts were used as controls
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A549 cells were related with chromatin condensation,
nuclear peripheral aggregation, and nuclear fragmentation
using an inverted fluorescence microscope (Fig. 8). The
results show that nuclear fragmentation and chromatin










































Fig. 5 Cellular viability detection of the PLL-MNP-labeled A549 lung cancer cells using PI and FDA double staining. a Untreated A549 cells
were used as controls. b–f Fluorescence images illustrated the A549 cells treated with various concentrations of PLL-MNPs (25, 50, 100, 200,












































Fig. 6 Immunofluorescent staining of the actin cytoskeleton of the PLL-MNP-labeled A549 lung cancer cells. a Untreated A549 cells were used
as controls. b–f The A549 cells treated with different concentrations of PLL-MNPs (25, 50, 100, 200, and 400 lg mL-1) were cultured for 48 h
in an RPMI-1640 medium. Cell nucleus was located by counterstaining with DAPI (blue). Scale bar 100 lm. (Color figure online)
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4 Conclusions
In the present study, the PLL-MNPs were fabricated with
excellent superparamagnetic properties and were used to
label human A549 lung cancer cells. The effects of
magnetic labeling on the biological behavior of A549 lung
cancer cells were also analyzed. The results showed that, in
comparison with previous studies, the fabricated PLL-
MNPs could enhance the cellular uptake in A549 lung






















































































































Fig. 7 a Cell cycle distribution of the examined cells. Unlabeled A549 cells were used as controls. b–f The A549 cells labeled with different
concentrations of PLL-MNPs (25, 50, 100, 200, and 400 lg mL-1) were cultured for 48 h








































Fig. 8 Fluorescent staining of PLL-MNP-treated A549 lung cancer cells. a Untreated A549 cells were used as controls. b–f Fluorescence images
illustrated the A549 cells treated with different concentrations of PLL-MNPs (25, 50, 100, 200, and 400 lg mL-1). Scale bar 100 lm
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to label cells did not affect the cell proliferation, viability,
and cytoskeleton (F-actin) organization in comparison with
unlabeled counterparts, and that cell apoptosis was slightly
affected by high concentrations of the PLL-MNPs. In
general, the present study provides the detailed insights
into the efficient magnetic IONP labeling of A549 lung
cancer cells and sheds light on the effects of magnetic
labeling on the biological behavior of these cells. The
results presented herein provide a new perspective for the
application of magnetic IONPs in the cell-targeted labeling
and noninvasive tracking behavior of A549 lung cancer
cells, as well as offering a promising approach for cell-
based lung cancer treatment.
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